Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BMO Capital Downgrades Verve Therapeutics to Market Perform, Lowers Price Target to $13.5

Author: Benzinga Newsdesk | June 27, 2025 12:09pm
BMO Capital analyst Kostas Biliouris downgrades Verve Therapeutics (NASDAQ:VERV) from Outperform to Market Perform and lowers the price target from $20 to $13.5.

Posted In: VERV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist